This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK, Feb. 26, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences:
34 TH Annual Cowen and Company Health Care Conference (Boston, MA)
Presentation Date: Monday, March 3
rd, 2014 Presentation Time: 2:50 pm ET
26 th Annual ROTH Conference (Dana Point, CA)
Presentation Date: Monday, March 10
th, 2014 Presentation Time: 12:00 Noon PT (3:00pm ET)
Live audio webcasts of these presentations will be accessible within the Investor Relations section of the Company's Website at
http://www.keryx.com/webcasts-presentations. An archived version of each webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate coordination complex), an oral, ferric iron-based compound. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx's New Drug Application (NDA), submitted to the FDA in 2013, is currently under review and has an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014. The Marketing Authorization Application (MAA) filing with the European Medicines Agency (EMA) is pending. Zerenex has also completed a Phase 2 study in the U.S. for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd., received marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease on January 17, 2014. Keryx is headquartered in New York City.
CONTACT: KERYX CONTACT:
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.